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ABSTRACT 
Sepsis, an uncontrolled inflammatory response is an important cause of death among the 
critically ill patients. Several lines of evidences have confirmed depression of myocardial 
function in sepsis which led researchers to focus intensely on myocardial dysfunction in 
sepsis. Several studies reported that LPS-induced pro-inflammatory cytokines, TNF-α and IL-
1β play a key role in sepsis-induced myocardial dysfunction. On the contrary, the secreted 
CCN matricellular proteins, in particular CCN2/CTGF (connective tissue growth factor), 
CCN5/WISP-2 (Wnt1-inducible signalling pathway protein-2) and the TGF-β superfamily 
cytokine, GDF-15 were shown to play cardioprotective roles in cardiac dysfunction and 
remodelling. In our present study, the effects of LPS have been investigated in adult mouse 
cardiac fibroblasts and cardiac myocytes. We assessed the mRNA levels and the protein 
levels of TNF-α, IL-1β, CCN2, CCN5 and GDF15 in the absence or presence of LPS in the 
adult mouse primary cardiac fibroblasts and cardiac myocytes by real-time q-PCR and 
Western blot analyses. We also investigated the viability of adult mouse primary cardiac 
myocytes after exposure to LPS (0.1 μg/ml and 10 μg/ml) for different periods of time (0, 
3,6,12 and 24 hours) by trypan blue exclusion assay. Real-time q-PCR demonstrates induction 
of mRNA levels of TNF-α and IL-1β in LPS-treated adult mouse cardiac fibroblasts and 
myocytes.  Particularly, in cardiac fibroblasts the induction of mRNA expressions of TNF-α 
and IL-1β were found to be much more robust than that in cardiac myocytes. Western blot 
analysis of extracts of cardiac fibroblasts revealed that the precursor protein levels of both 
TNF-α and IL-1β were significantly induced in the LPS stimulated cardiac fibroblasts 
compared to non-stimulated cells. However, in cardiac myocytes the precursor protein levels 
of TNF-α and IL-1β remained unchanged in LPS-treated cells compared to control cells. In 
addition, gene expression analysis revealed down-regulation of CCN2 and CCN5 in LPS 
stimulated cardiac fibroblasts, whereas mRNA levels of GDF15 were found to be up-
regulated in LPS-treated cardiac myocytes. Assessment of LPS-induced cell death of adult 
cardiac myocytes demonstrates significant decrease of cell viability in LPS-treated cardiac 
myocyte cultures. In our future studies, we will investigate the cytoprotective effects of 
recombinant CCN2, CCN5 and GDF15 at LPS-induced cell death in cardiac cell cultures. It 
would also be interesting to delineate the effects of LPS in vivo using CCN2-transgenic 
mouse model with cardiac specific overexpression of CCN2. 
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ABBREVIATIONS 
SIRS                                  Systemic inflammatory response syndrome 
LVSWI                              Left ventricular stroke work index  
TTE                                   Transthoracic echocardiography  
LVEF                                 Left ventricular ejection fraction  
TEE                                   Transesophageal echocardiography  
LPS                                    Lipopolysaccharide 
TNF-α                                Tumor Necrosis Factor-α 
IL-1β                                  Interleukin 1β 
CTGF                                 Connective Tissue Growth Factor 
WISP2                                Wnt-1 Inducible Signalling Pathway 2 
GDF15                               Growth Differentiation Factor 15 
NO                                      Nitric Oxide 
TLR-4                                Toll Like Receptor-4 
LBP                                    LPS Binding Protein 
MD-2                                  Myeloid Differential Protein-2   
CD-14                                Cluster of Differentiation-14 
LV                                      Left ventricle 
SERCA2a                           Sarcoplasmic reticulum Ca
2+
 ATPase  
iNOS                                   inducible Nitric Oxide Synthase 
ECM                                   Extracellular Matrix 
PDGF                                 Platelet-derive Growth Factor 
AT-1                                   Angiotensin-II type 1 
IGFBD                                Insulin-like Growth Factor Binding Domain 
vWC                                    von Willebrand factor type-C   
TPS-1                                  Thrombospondin Type-1 
CT                                       C-terminal 
TGF-β                                 Transforming Growth Factor 
FAM                                    6-carboxy fluorescin dye  
NFQ                                     Nonfluorescent quencher 
FRET                                   Fluorescence Resonance Energy Transfer 
RT                                        Reverse Transcription 
GAPDH                               Glyceraldehyde 3-phosphate Dehydrogenase       
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SDS                                       Sodium Dodecyl Sulfate 
PVDF                                    Polyvinylidene Fluoride 
HRP                                      Horseradish Peroxidase 
qPCR                                    Quantitative Polymerase Chain Reaction 
ROS                                      Reactive Oxygen Species 
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1. INTRODUCTION 
 
1.1 Sepsis 
According to prevailing theory, sepsis is an uncontrolled inflammatory response [1-3]. In 
1879-80, Luis Pasteur discovered for the first time that bacteria existed in blood from patients 
with puerperal septicemia. Survival of a woman led Pastuer to articulate “Natura medicatrix 
won the victory”, a notion that body responds systematically to sepsis to fight off the 
pathogens (Fig. 1.1). However, sepsis has now appeared as an important cause of death in 
critically ill patients [4]. The occurrence of sepsis is increasing every year and lately it has 
been published as 132 per 100000 populations with 50% mortality approach [5]. 
 
Figure 1.1 From bacteria to disease [6]. Barred lines = Inhibition and Arrows = Activation 
and consequences. 
 
A consensus conference defined sepsis as “the systemic inflammatory response syndrome 
(SIRS) that occurs during infection [1]. ” Table 1.1 quotes the current criteria to establish the 
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diagnosis of systematic inflammatory response syndrome (SIRS), sepsis and septic shock [1, 
6]. 
Table 1.1 
SIRS 
A response from the body to an infectious or noninfectious insult. It has actually pro and anti-
inflammatory components though the definition refers to it as an ‘‘inflammatory’’ response 
[7].           
Two or more of the following conditions: 
 Temperature >38.5°C or <35°C      
 Heart rate >90 beats per minute 
  Respiratory rate >20 breaths per minutes or Atrial CO2 <32 mm Hg or need for 
mechanical ventilation 
  White blood cell count >12 000/mm3 or 4000/mm3  or 10% < immature (band) forms 
Sepsis              
SIRS and documented infection (culture or gram-stain of blood, sputum, urine, or normally 
sterile body fluid positive for pathogenic organisms; or focus for infection identified by 
visual inspection, e.g. ruptured bowel with free air or bowel contents found in the abdomen at 
surgery or a wound with purulent discharge) 
Severe sepsis     
Sepsis and at least one of the signs of organ hypoperfusion or organ dysfunction: 
 Areas of mottled skin 
 Capillary refilling time ≥3 s 
 Urinary output of <0.5 ml/kg for at least 1 h or renal replacement therapy                                                                                                
 Lactate >2 mmol/L 
 Abrupt change in mental status or abnormal electroencephalogram findings 
 Platelet count <100000/ml or disseminated intravascular coagulation 
 Acute lung injury/acute respiratory distress syndrome 
 Cardiac dysfunction (echocardiography) 
 
Septic shock         
Severe sepsis and one of the following conditions: 
 Mean arterial pressure <60 mm Hg (<80 mm Hg if previous hypertension) after 20-30 
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ml/kg starch or 40-60 ml/kg saline solution, or pulmonary capillary wedge pressure 
between 12 and 20 mm Hg 
 Need for dopamine >5 µg/kg.min or norepinephrine or epinephrine of <0.25 
µg/kg.min to maintain mean arterial pressure above 60 mm Hg (80 mm Hg if previous 
hypertension) 
Refractory septic shock  
Need for dopamine at >15 µg/ kg.min, or norepinephrine or epinephrine at >0.25 µg/kg.min 
to maintain mean arterial pressure .60 mm Hg (80 mm Hg if previously hypertensive) 
 
 
1.2 Sepsis-induced Cardiac Dysfunction 
In 1951, Waisbren first described  that sepsis causes the cardiovascular dysfunction [8].  
Recent evidences have confirmed depression of myocardial function in sepsis and reduced 
cardiac index or echocardiographic evidence of cardiac dysfunction are now considered 
essential criteria for diagnosis of severe sepsis [6, 9] which led researchers to focus intensely 
on myocardial dysfunction in sepsis.  
 
The concept of depressed myocardial function in sepsis emerged from studies utilizing 
radionuclide cineangiography performed by Parker et al. in a group of septic shock patients. 
They showed significant depression of myocardial function [10]. Their group  also showed 
that patients with severe sepsis and septic shock had intrinsically impaired myocardial 
performance as determined by assessment of left ventricular stroke work index (LVSWI) in 
response to fluid infusion [11]. Similar deviations appeared in the right ventricle [12]. Septic 
shock patient displays reduced left ventricular contractility (abnormal left ventricular stroke 
work index) and left ventricular dilatation.  
 
More recently, echocardiography is used to characterize cardiac dysfunction in severe sepsis 
and septic shock. Several research data have stated impaired left ventricular systolic and 
diastolic function. In a longitudinal study, transthoracic echocardiography (TTE) showed 
significantly depressed left ventricular ejection fraction (LVEF) in all septic shock patients 
[13]. Transesophageal echocardiography (TEE) reported a 60% incidence of global left 
ventricular hypokinesia in a series of patients [14]. Acute and reversible left ventricular 
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dilatation with systolic left ventricular dysfunction was reported in a group of septic patients 
followed with serial TEE [15].  
 
Cardiac depression during sepsis is probably multi-factorial. Early investigators claimed that 
myocardial ischemia was responsible for myocardial dysfunction though it has been excluded 
as a cause by subsequent studies. These studies reported that high coronary blood flow, net 
myocardial lactate extraction and diminished coronary artery–coronary sinus oxygen 
difference emerge during sepsis [16]. The microcirculation deviates during sepsis with 
endothelial disruption and misdistribution of blood flow [17]. Sepsis causing regional 
ischemia may also alter microvascular blood flow in the heart [18, 19]. 
  
A circulating myocardial depressant factor in sepsis was first proposed in the 1970s [20, 21]. 
In 1985, Parrillo et al. showed that serum obtained from patients with septic shock developed 
a significant depression in an “in vitro cardiomyocyte performance’’ [22]. In a study of 
neonatal rat cardiac myocyte cultures, the ultrafiltrate from septic patients caused 
significantly higher amounts of pro-inflammatory cytokines and anaphylatoxins release, 
proposing an involvement of a number of circulating factors in sepsis-induced myocardial 
depression [23]. 
 
Endotoxin i.e., lipopolysaccharide (LPS) released by gram-negative bacteria is the key 
mediator of the cardiovascular dysfunction in septic shock [24]. After endotoxin 
administration in the heart, the typical haemodynamic pattern of severe sepsis developed with 
an increased heart rate, an increased cardiac index and a low systematic vascular resistance. 
After volume loading, a reduction in LVEF and LV performance developed [24]. Toll-like 
receptor-4 plays a pivotal role in endotoxin-induced cardiac dysfunction through activation of 
NF-ΚB pathway and causes the release of various cytokines and the progression of the 
inflammatory response [25, 26]. Several studies reported that the inflammatory cytokines, 
TNF-α and IL-1β play a key role in sepsis-induced myocardial dysfunction. The mechanism 
of TNF-α induced cardiac dysfunction is not well elucidated, but probably alteration of 
calcium homeostasis and increased synthesis of nitric oxide (NO) appear to be key players. 
IL-1β causes significant concentration-dependent depression of maximum extent and peak 
velocity of myocyte shortening [27]. NO has a direct effect on cardiac contractility [28-30]. 
Overproduction of NO adversely affects myocardial contractile function [31]. NO has also 
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been reported to depress myocardial energy production and cause apoptosis of cardiac 
myocytes [32, 33]. Sepsis induced cardiac dysfunction are given in a flow chart (Fig. 1.2) 
 
 
Figure 1.2 Sepsis-induced cardiac dysfunction. During sepsis changes in the macro and 
microcirculation, autonomic dysfunction, and inflammation-induced intrinsic myocardial 
depression impair cardiac performance. The mechanisms of myocardial depression include 
down-regulation of adrenergic pathways, disturbed intracellular calcium (Ca
2+
) trafficking 
and impaired electromechanical coupling at the myofibrillar level. Mitochondrial dysfunction 
is thought to play a central role in this sepsis-induced organ dysfunction [34]. 
 
 
1.3 Endotoxin or Lipopolysaccharide (LPS) 
Louis Pasteur (1822–1895)  proved first beyond any doubt that microbes (the term 
‘microbiology’ was created by Pasteur) can cause an infectious disease [35]. In 1886, Ludwig 
Brieger (1849–1919) discovered  that germs secrete poisonous products, termed ‘toxins’, 
[36]. Robert Koch, who had identified  V. cholerae in 1884, claimed that a poisonous 
substance played a pivotal role in cholera pathogenesis [37]. Koch encouraged one of his 
coworkers, Richard Pfeiffer (1858–1945), to investigate the nature of the toxins involved in 
cholera pathogenesis. During his studies, Richard Pfeiffer (1858–1910) discovered that 
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lysates of heat-killed bacteria of the cholera-inducing infectious agent Vibrio cholerae 
developed toxic shock reactions in guinea pigs and eventually the animals died [38]. Pfeiffer 
formulated the concept that V. cholerae consists of a heat-stable toxic substance in 
association with the insoluble part of the bacterial cell [39, 40] and he named this substance 
endotoxin (from the Greek ‘endo’ meaning ‘within’). Pfeiffer proposed that both Gram-
negative and Gram-positive bacteria consist of endotoxin. The Italian pathologist Eugenio 
Centanni (1863–1948), summarized Pfeiffer’s work “Thus, we can conclude that the whole 
family of bacteria possesses essentially the same toxin … upon which depends the typical 
picture of the general disturbances caused by bacterial infections” [41]. Also, Centanni 
recognized the intimate relationship between the pyrogenic and toxic properties of endotoxin, 
which he found chemically inseparable. William B. Coley (1862–1936) showed that mixtures 
of killed bacteria (Serratia marcescens and Streptococci spp.) caused fever as well as induced 
remissions of certain malignant tumors in humans [42] which helped to discover tumor-
necrosis factor (TNF) many years later. 
 
Figure 1.3 Gram-negative bacterium, Escherichia coli (a) with lipopolysaccharide (LPS; 
endotoxin) in the bacterial cell wall (b) and architecture of LPS (c) along with its toxic centre, 
the lipid A component (d) [43].  
 
After intensive studies today we know  that endotoxin is structurally an essential component 
of the outer membrane of gram-negative bacteria [44]. Lüderitz and Westphal designated this 
endotoxin as lipopolysaccharide (LPS) beacuse of its chemical composition [45]. It consists 
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of an amphipathic lipid A component and hydrophilic polysaccharides of the core and O-
antigen [46, 47].  Several studies reported that lipid A had the toxic and pyrogenic properties 
of endotoxin [44]. Lipid A is a glycophospholipid, with unique structural features. For 
example, lipid A of Escherichia coli’s LPS consists of a 1,4′-bisphosphorylated β1,6-linked 
D-glucosamine (D-GlcN) or a Glc2,3N disaccharide, which carries four residues of (R)-3-
hydroxytetradecanoic acid at positions 2, 3, 2′ and 3′, two of which are acylated at the 3-
hydroxy group by dodecanoic acid (2′) and tetradecanoic acid (2′). The hydroxy group at 
carbon 4 is free whereas that at 6′ is the attachment site for the polysaccharide component. 
Lipids A molecules of other gram-negative bacteria have the similar architectural principle 
though they may differ in structural details (Fig. 1.3) [48].  E. coli lipid A has more endotoxic 
effects than any other synthetic molecules although any modification of the structure of E. 
coli lipid A yielded products of lower endotoxicity. Therefore, bisphosphoryl lipid A is 100-
fold more toxic than monophosphoryl lipid A (MPL), and A partial lipid A structure (lacking 
the two secondary acyl groups) is entirely devoid of toxicity in the human system [49].  
 
Upon infection, LPS released from Gram-negative bacteria is first recognized by the host 
immune cells such as macrophages, neutrophils, mucosal epithelial cells and endothelial 
cells. This recognition initiates several intracellular signal transduction pathways i.e., cell 
activation and production of a variety of endogenous mediators, including pro-inflammatory 
cytokines, adhesion molecules, acute phase proteins, nitric oxide and prostaglandins [50, 51]. 
Abnormal host responses may contribute to tissue damage, organ failure i.e., symptoms 
characteristic of septic shock.  
 
The Toll protein first discovered in Drosophila, plays a pivotal role in the determination of 
the dorsal–ventral patterning during embryogenesis [52, 53] which is an early form of 
defence in the innate immune system [54, 55]. The mammalian tolls like receptors (TLRs) are 
the first line of defence expressed by cells of the innate immune system. Lipid A is the main 
pathogen associated molecular pattern of LPS. Using the C3H/HeJ mouse strain Beutler’s 
group demonstrated that TLR4 is a key sensor for LPS [52]. LPS stimulation of mammalian 
cells involves several proteins including the LPS binding protein (LBP), CD14, MD-2 and 
TLR4 [53, 56]. LBP is a soluble shuttle protein. LBP directly binds to LPS and mediates the 
association between LPS and CD14 [54, 55]. CD14 is a glycosyl phosphatidylinositol- 
anchored protein, which also exists in a soluble form. CD14 mediates the transfer of LPS to 
the TLR4/MD-2 receptor complex and regulates LPS recognition [50]. MD-2 is a soluble 
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protein and it non-covalently associates with TLR4. However, it can directly form a complex 
with LPS in the absence of TLR4 [57-59]. Although no evidence suggests that TLR4 can 
bind LPS directly, TLR4 can enhance the binding of LPS to MD-2 [60]. Therefore, LPS 
stimulation of TLR4, includes the participation of several molecules and the currently 
favored model is given below (Fig. 1.4) [56, 61]. MyD88 was first described as a myeloid 
differentiation primary response gene [62]. 
 
Figure 1.4 Overview of LPS/TLR4 signalling. LPS recognition is mediated by LBP and 
CD14 following by TLR4/MD-2 receptor complex. LPS/TLR4 signalling can be divided into 
MyD88-dependent and MyD88-independent pathways, which mediate the activation of pro-
inflammatory cytokines and Type I interferon genes [51]. 
 
LPS plays a pivotal role in sepsis associated depression of myocardial function [63]. 
Suffredini et al. confirmed the development of cardiac dysfunction by giving endotoxin to 
healthy human volunteers [24].  Jianhui et al. interestingly  demonstrated that altered volume 
loading conditions caused the septic cardiac abnormalities within 6 hours of LPS 
administration and LV (Left Ventricle) contractility increased at 6 hour period [64]. These 
data differ with previous murine studies that reported decreased myocardial contractility after 
LPS administration. However, mostly load-dependent indices of contractility were used to 
assess function, such as ejection fraction and maximal systolic pressure increment (dP/dtmax) 
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[65, 66]. This finding is consistent with previous studies. These studies also demonstrated 
reductions in loading conditions in dog and calves given LPS [67, 68]. 
 
LPS mediating tumor necrosis factor (TNF)-α and interleukin (IL)-1β, cause septic 
myocardial dysfunction through sarcoplasmic reticulum calcium leakage [69, 70]. 
Sarcoplasmic reticulum Ca
2+
 ATPase (SERCA2a) plays a pivotal role in cardiac function via 
maintenance of calcium homeostasis. TNF-α decreased SERCA2a expression via enhancing 
SERCA2a promoter methylation in HL-1 murine atrial cells [71]. Lancel et al. reported that 
LPS-induced proximal mediators of apoptotic response i.e. caspase activation, sarcomere 
destruction and contractile dysfunction in rat LV cardiomyocytes [72]. LPS also impaired 
SERCA and mitochondria-dependent calcium uptakes [73]. TLR-4 expressed in 
cardiomyocytes plays a key role in LPS-induced myocardial dysfunction [74] 
 
1.4 Tumor Necrosis Factor (TNF)-α 
TNF-α plays a key role in the pathogenesis and progression of myocardial ischemia/ 
reperfusion injury and heart failure [75]. It was first identified as an endotoxin-induced serum 
factor that caused necrosis of tumors [76]. TNF-α is a part of the innate immune system 
response to different forms of stress i.e., infection, trauma, ischemia/reperfusion (I/R). 
Normally TNF-α concentration is low both in the circulation and the heart in healthy 
individuals [77-79].  A enormous amount of preformed homotrimaric soluble TNF-α is 
released  from macrophages, lymphoid cells, mast cells, endothelial cells (EC), fibroblasts 
within minutes by inflammatory stimuli i.e., bacterial (lipopolysaccharides and other 
products), viral [80], parasite infections [81-83] or acute injury, such as ischemia [84]. Acute 
myocardial I/R also causes a massive release of TNF-α from the heart [85-88]. Excessive 
TNF-α expression in the heart induces cell death, contractile dysfunction, dilated 
cardiomyopathy and fibrosis via TNF-α receptor type 1 [75]. 
  
1.5 Interleukin (IL)-1β 
Interleukin (IL)-1β (15KD) is the prototypic, pro-inflammatory cytokine; able to induce a 
large portfolio of genes in a wide variety of cell types, usually not expressed in normal 
physiological condition [89]. It was first identified as the first “endogenous pyrogen” due to 
exerting fever-inducing effects in both rabbits and humans [90, 91]. Consistent induction and 
activation of  IL-1β is observed in many inflammatory conditions and may contribute to 
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tissue injury in many diseases e.g., sepsis, rheumatoid arthritis and inflammatory bowel 
disease [92]. IL-1β increases the expression of inducible nitric oxide synthase (iNOS) and 
cyclo-oxygenase (COX)-2. IL-1β also increases many other cytokines expressions, such as 
TNF-α, the chemokines and adhesion molecules. In addition, IL-1β increases the expression 
of various tissue proteases and matrix metalloproteases and inhibits the synthesis of 
proteoglycans [93, 94]. IL-1β might be involved in atherothrombotic disease by mediating 
atheromatous lesions formation, vascular inflammation and plaque destabilization. IL-1β 
acutely regulates the inflammatory response in myocardial infarction and enhances the 
expression of matrix metalloproteinases following the development of adverse remodeling. 
IL-1β signaling might also be involved in cardiac dysfunction promoting myocardial 
hypertrophy and inducing cardiomyocyte apoptosis [95]. 
 
1.6 Connective Tissue Growth Factor (CTGF) or CCN2 
CTGF belongs to a growing family of genes, called CCN family of genes. CCN proteins are 
modular and secreted extracellular matrix (ECM) associated proteins. They are involved in 
regulating miscellaneous cellular activities such as adhesion, migration, mitogenesis, 
differentiation, and survival. The acronym CCN was coined by Peter Bork   in 1993 which 
stands for CYR61, CTGF, NOV, the first three proteins of CCN family of genes [96]. CCN 
proteins share 38 conserved cysteine residues with approximately 40 to 60% sequence 
similarity and about 30 to 50% overall amino acid sequence identity [97]. Connective tissue 
growth factor (CTGF) holds the second position among six CCN proteins. It has differently 
been known such as FISP12, Hcs24, ecogenin, IGM2, IGFBP8, IGFBP-rP2 and CCN2 [96, 
98, 99]. Bradham et al. first isolated CCN2 from human umbilical vein endothelial cell 
culture supernatants using an anti-platelet-derive growth factor (PDGF) antibody. CCN2 is a 
38 KD monomeric protein composed of 349 residues and its four distinct structural modules 
(Fig. 1.5) offer multi-functionality [100]. This glycoprotein is involved in diverse cellular 
responses including extracellular matrix production, cell proliferation and growth, cell 
adhesion, apoptosis, or cell viability depending on cell type and cellular context [101].  
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Figure 1.5 (A) CCN2 gene structure downstream of the transcription start site. Grey bars 
indicate untranslated regions and black lines indicate introns (i). Colored bars denote Exons 
(E). (B) CCN2/CTGF protein and protease cleavage sites with four distinct modules; IGFBP, 
Insulin-like growth factor binding protein; VWF-C/CR, von Willebrand factor type 
C/chordin-like cystein-rich; TSP1, thrombospondin 1; CT, carboxy terminal [102]. 
 
CCN2 is the most studied member of the CCN family in the cardiovascular system. CCN2 
may play a vital role in cardiac remodeling because of its consistent up-regulation in models 
of cardiac injury, hypertrophy, and fibrosis and its profound effects on cardiomyocytes, 
fibroblasts, and endothelial cells [103, 104]. Our group demonstrated that CCN2 increases the 
tolerance of the heart towards ischemia/reperfusion injury as well as to cardiomycytes 
towards hypoxia/reoxygenation injury [105]. Our group also demonstrated that Angiotensin-
II-induced myocardial CCN2 contributes to myocardial remodeling in heart failure mediated 
via Angiotensin-II type 1 (AT1) receptors situated on cardiac fibroblasts [106]. 
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1.7 Wnt1-inducible Signaling Pathway 2 (WISP-2) or CCN5 
CCN5 is a unique member of the CCN family of genes [107]. All other CCN proteins contain 
four distinct domains: (i) insulin-like growth factor-binding domain (IGFBD), (ii) von 
Willebrand factor type-C (vWC), (iii) thrombospondin type-1 (TPS-1), and (iv) C-terminal 
domain (CT), whereas CCN5 lacks the CT domain (Fig 1.6). It has been demonstrated that 
the CT domain regulates the proliferative activity of CCN1 and CCN2 and lacking this CT 
domain in CCN5 may contribute to its converse effects compared to CCN1 and CCN2 [108-
110]. Yoon et al. demonstrated that over-expressed CCN5 inhibits cardiac hypertrophy and 
fibrosis by blocking the TGF-β-SMAD signaling pathway in response to pathological stimuli 
both in vitro and in vivo [111]. 
 
 
Figure 1.6 Structure of CCN family members. The CCN family members, CCN1 (Cyr61), 
CCN2 (CTGF), CCN3 (nov), CCN4 (WISP-1), CCN5 (WISP-2) and CCN6 (WISP-3), 
whereas CCN5 differs from other CCN proteins by lacking CT domain [112]. 
 
 
1.8 Growth Differentiation Factor 15 (GDF15) 
Growth differentiation factor 15 (GDF15) is a member of the transforming growth factor β 
(TGF-β) superfamily; is a secreted macrophage inhibitory cytokine mainly expressed by 
activated macrophages by inflammatory stimuli. Normally, expression of GDF15 is abundant 
in the placenta and the prostate, but not in many other organs, including the heart.  However, 
IL-1, TNF-α and TGF-β in macrophages induce GDF15 expression rapidly, thereby 
modulating macrophage activation and inflammation. p53, a tumor suppressor protein, also 
induces GDF15 expression and acts as a growth inhibitory molecule in tumor cells [113-115]. 
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Kemph et al demonstrated that over-expression of GDF15 in cardiomyocytes increases the 
tolerance of the heart towards ischemia/reperfusion (I/R) via the nitric oxide-peroxynitrite 
dependent signaling pathway [116]. Xian Su et al. also demonstrated that GDF15 plays a role 
as a novel anti-hypertrophic factor in the heart through a mechanism involving SMAD 
protein [117]. Our group also demonstrated that cardiomyotes of CNN2 over-expressing 
transgenic mice increased expression of GDF15 significantly which may constitute an 
autocrine loop that activates SMAD2 protein and inhibits cardiac myocyte growth [105]. 
 
 
2. AIM OF THE STUDY 
The purpose of the study was to investigate how LPS regulates the expression of TNF-α, IL-
1β, CCN2, CCN5 and GDF15 in adult cardiac myocytes and cardiac fibroblasts. In addition, 
it would also be interesting whether LPS results in cell death in adult mouse cardiac 
myocytes. Aims of study are given below elaborately.  
 To isolate adult mouse cardiac myocytes and cardiac fibroblasts. 
 To maintain adult mouse cardiac myocytes and cardiac fibroblasts cell cultures in 
vitro. 
 To investigate the effects of LPS on the adult mouse cardiac myocytes and fibroblasts. 
 To study the effects of LPS on the regulation of mRNA levels of TNF-α and IL-1β in 
adult mouse cardiac myocytes and fibroblasts.  
 To study the effects of LPS on the regulation of mRNA levels of CCN2, CCN5 and 
GDF15 in adult mouse cardiac myocytes and fibroblasts. 
 To study the effects of LPS on the regulation of protein levels of TNF-α and IL-1β in 
adult Mouse cardiac myocytes and fibroblasts. 
 To study the effects of LPS on regulation of protein levels of CCN2, CCN5 and 
GDF15 in adult mouse cardiac myocytes and fibroblasts. 
 To study the effects of LPS on the viability of adult mouse cardiac myocytes. 
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3. MATERIALS 
 
3.1 Isolation of Adult Mouse Cardiac Myocytes and Fibroblasts 
 
 
 
                                                                                                                          
MEM (Minimum Essential Medium) with glutamine........................................................Gibco 
DMEM (Dulbecco's Modified EagleMediu)......................................................................Gibco 
Calf Serum.....................................................................................................................HyClone 
 Fetal Calf Serum...............................................................................................................Sigma 
Gentamycin..........................................................................................................Sanofi Aventis 
Bovine serum albumin (endotoxin and lipid free).............................................................Sigma 
CaCl2 (1 M).......................................................................................................................Sigma 
BDM (2.3-Butanedione monoxime; 500 mM)..................................................................Sigma 
Penicillin-G........................................................................................................................Sigma 
Na-ATP (200 mM).............................................................................................................Sigma 
Laminin........................................................................................................................Invitrogen 
 
 
 
Steri Cycle CO2 Incubator…………………………………………………….Thermo Scintific 
Perfusion System………………………………………………………………Watson Marlow 
Laminar flow culture hood………………………………………………………………Holten 
Surgery scissors……………………………………………………………………….Aesculap 
 
 
 
Perfusion Buffer (1L) 
NaCl................................................................................................................................120 mM 
KCl...............................................................................................................................14.75 mM 
KH2PO4...........................................................................................................................0.6 mM 
Na2HPO4 2H2  .............................................................................................................0.589 mM 
MgSO4 7H20..................................................................................................................1.22 mM 
NaHCO3.........................................................................................................................4.64 mM 
Chemicals                                                                                                 Suppliers 
Solutions                                                                                                     Amount 
Equipments                                                                                              Suppliers 
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Taurine.........................................................................................................................29.98 mM 
BDM..............................................................................................................................9.89 mM 
Glucose..........................................................................................................................5.55 mM 
Na-HEPES........................................................................................................................10 mM 
dH2O…………………………………………………………………………………..Up to 1L 
 
Digestion Buffer (50ml) 
Perfusion buffer...................................................................................................................50 ml 
Collagenase 2...................................................................................................................120 mg 
 
Stopping Buffer (20 ml) 
Perfusion buffer...................................................................................................................18 ml 
Calf Serum............................................................................................................................2 ml 
CaCl2 (100 mM)..................................................................................................................2.5 µl 
 
Stopping Buffer for Ca-introduction (30 ml) 
Perfusion buffer...................................................................................................................27 ml 
Calf Serum............................................................................................................................3 ml 
     A) 10 μl of 100 mM CaCl2 in 10 ml Stopping Buffer. 
     B) 40 μl of 100 mM CaCl2 in 10 ml Stopping Buffer. 
     C) 90 μl of 100 mM CaCl2 in 10 ml Stopping Buffer 
 
Myocyte Plating Medium  
MEM with HBS...............................................................................................................42.5 ml 
Penicillin............................................................................................................................0.5 ml 
BDM......................................................................................................................................1 ml 
ATP....................................................................................................................................0.5 ml 
Calf Serum............................................................................................................................5 ml 
 
Myocyte Long-Term Culture Medium 
MEM with HBSS.............................................................................................................48.5 ml 
Penicillin............................................................................................................................0.5 ml 
BDM......................................................................................................................................1 ml 
BSA....................................................................................................................................0.5 ml 
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3.2 RNA Isolation 
 
 
 
RNeasy®
 
Mini Kit............................................................................................................Qiagen 
β-mercaptoethanol..............................................................................................................Sigma 
TRIzol® Reagent…………………………………………………………………….Invitrogen 
Chloroform……………………………………………………………………………….Sigma 
Glycogen……………………………………………………………………………..Invitrogen 
 
 
 
Centrifuge and rotor capable of reaching up to 12000xg………………………………Biofuge 
Heating Block…………………………………………………………………………...Techne 
ND1000 Spectrophotometer…………………………………………………………NanoDrop 
 
3.3 Reverse Transcription 
 
 
TaqMan Reverse Transcription Reagents…………………………………Applied Biosystems 
 
 
 
Thermo Cycler…………………………………………………………….Applied Biosystems 
 
3.4 TaqMan Real-Time PCR 
 
                                                                                                               
 
TaqMan
 
Real-Time PCR amplification 
Taqman 2x PCR master mix........................................................................Applied Biosystems 
Taqman gene expression assays (20x)…………………………………….Applied Biosystems 
a) CTGF (Mm01192933_g1) 
Chemicals                                                                                                 Suppliers 
Equipments                                                                                              Suppliers 
Chemicals                                                                                                 Suppliers 
Chemicals                                                                                                 Suppliers 
Equipments                                                                                              Suppliers 
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b) WISP-2 (Mm00497471_m1) 
c) GDF-15 (Mm00442228-m1) 
d) TNF-α (Mm00443260_g1) 
e) IL-1β (Mm00434228_m1) 
 
 
 
TaqMan
 
Real-Time PCR amplification 
MicroAmp™ Optical 96-well reaction plate……………………………...Applied Biosystems 
MicroAmp™ Clear Adhesive Film………………………………………..Applied Biosystems 
7900HT Real-Time PCR Machine………………………………………...Applied Biosystems 
Sequence Detection Sytem (SDS) 2.2 software…………………………...Applied Biosystems 
Microsoft Excel 2007………………………………………………………………...Microsoft 
GraphPad Prism version 4……………………………………………………………GraphPad 
 
3.5 Western Blot Analysis 
 
 
 
30% Acrylamide/Bis Solution, 37.5:1…………………………………………………Bio-Rad 
Trizma Base……………………………………………………………………………...Sigma 
Glycine…………………………………………………………………………………...Sigma 
Glycerol…………………………………………………………………………………..Sigma 
SDS…………………………………………………………………………………..Invitrogen 
MiliQ H20.......................................................................................................................MiliPore 
AmmoniumPersulfate........................................................................................................Sigma 
TEMED…………………………………………………………………………………..Sigma 
Methanol…………………………………………………………………………………Sigma 
PVDF Transfer Membrane……………………………………………………..GE HealthCare 
Whatman Paper………………………………………………………………………...Bio-Rad 
Nonfat Dry Milk……………………………………………………………………….Bio-Rad 
Casein………………………………………………………………………..Thermo Scientific 
10x PBS…………………………………………………………………………………..Lonza 
Equipments                                                                                              Suppliers 
Chemicals                                                                                                 Suppliers 
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10x TBS…………………………………………………………………………………..Lonza 
Tween-20 Detergent……………………………………………………………………...Sigma 
LumiGlo……………………………………………………………………………………KPL 
 
Primary Antibodies 
IL-1β (Catalog No: 8689)………………………………………………………..Cell Signaling 
TNF-α (Catalog No: 3707)………………………………………………………Cell Signaling 
CCN2 (Catalog No: Sc-14939)……………………………………………………... Santa Cruz 
CCN5 (Catalog No: Sc-8868)………………………………………………………. Santa Cruz 
GDF15 (Catalog No: ABIN372779)………………………………………...Antibodies-online 
 
Secondary Antibodies 
Anti-rabbit IgG HRP……………………………………………………………GE HealthCare 
Anti-goat IgG HRP………………………………………………………………….Santa Cruz 
                
 
 
 
Lysis Buffer (4ml) 
SDS (10 %)………………………………………………………………………………400 µl 
Tris-HCl (1M; pH 7.4)…………………………………………………………………….40 µl 
dH2O…………………………………………………………………………………Up to 4 ml 
 
12% Separating Gel (15 ml)  
dH2O……………………………………………………………………………………...4.9 ml 
Acrylamide Mix (30%)…………………………………………………………………….6 ml 
Tris base (1.5; pH 8.8)…………………………………………………………………...3.8 ml 
SDS (10%)…………………………………………………………………………….0.150 ml 
Ammonium Persulfate (10%)…………………………………………………………0.150 ml 
TEMED………………………………………………………………………………..0.006 ml 
 
5% Stacking Gel (5 ml) 
dH2O……………………………………………………………………………………...3.4 ml 
30% Acrylamide Mix………………………………………………………………….0.830 ml 
1.5 Tris base (pH 6.8)………………………………………………………………….0.630 ml 
Solutions                                                                                                        Amont 
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10% SDS………………………………………………………………………………0.050 ml 
10% Ammonium Persulfate…………………………………………………………...0.050 ml 
TEMED………………………………………………………………………………..0.005 ml                                                                                                                            
 
2x Loading Buffer (100ml) 
Tris HCl pH 6.8………………………………………………………………………..125 mM 
SDS………………………………………………………………………………………….4% 
Glycerol…………………………………………………………………………………….10% 
Bromophenol Blue………………………………………………………………………...0.1% 
β-Mercaptoethanol……………………………………………………………………….100 µl 
dH2O………………………………………………………………………………Up to 100 ml 
 
5x Running Buffer (1L) 
Tris Base……………………………………………………………………………………15 g 
Glycine……………………………………………………………………………………..72 g 
SDS………………………………………………………………………………………….5 g 
dH2O………………………………………………………………………………….Up to 1L 
 
10x Blotting Buffer (1L) 
Tris Base…………………………………………………………………………………30.3 g 
Glycine……………………………………………………………………………………144 g 
dH2O…………………………………………………………………………………..Up to 1L 
 
Blotting Buffer (1L) 
10x Blotting Buffer ……………………………………………………………………..100 ml 
Methanol………………………………………………………………………………...200 ml 
dH2O.…………………………………………………………………………………Up to 1L 
 
10xPBS (Ph 7.4) Buffer 
NaCl………………………………………………………………………………………..80 g 
KCl………………………………………………………………………………………...2.0 g 
Na2HPO4………………………………………………………………………………….14.4 g 
KH2PO4…………………………………………………………………………………...2.4 g 
dH2O…………………………………………………………………………………..Up to 1L 
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10x TBS (pH 7.4) Buffer 
Trisbase.................................................................................................................................30 g 
NaCl......................................................................................................................................88 g 
KCl..........................................................................................................................................2 g 
dH2O…………………………………………………………………………………..Up to 1L 
 
PBST Buffer (1L) 
10x PBS………………………………………………………………………………….100 ml 
Tween 20 detergent………………………………………………………………………...1 ml 
dH2O…………………………………………………………………………………..Up to 1L 
 
TBST Buffer (1L) 
10x TBS…………………………………………………………………………………100 ml 
Tween 20 detergent………………………………………………………………………...1 ml 
dH2O…………………………………………………………………………………..Up to 1L 
 
Blocking Buffer (6ml) 
5% Milk Buffer in PBST or TBST 
5% Casein Buffer in PBST 
 
 
 
 
Ultrasonic Cell Disrupter…………………………………………………………….Microsom 
ELISA Reader Machine………………………………………………………………….Victor 
Gel Electrophoresis Apparatus………………………………………………………...Bio-Rad 
Electronic Transfer Apparatus…………………………………………………………Bio-Rad 
Chemiluminescence Apparatus………………………………………………………….Kodak 
 
 
  
Equipments                                                                                              Suppliers 
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3.6 Cell Viability Test 
 
 
 
Trypan Blue………………………………………………………………………………Sigma 
 
 
 
 
0.45 µm non-pyrogenic Filter …………………………………………………………Milipore 
Light Microscope………………………………………………………….Leica Microsystems 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chemicals                                                                                                 Suppliers 
Equipments                                                                                              Suppliers 
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4. METHODS 
4.1 Isolation of Adult Mouse Cardiac Myocytes and Cardiac 
Fibroblasts 
Isolation of cardiac myocytes or fibroblasts was performed according to the protocol 
published by Timothy D. O’Connel with minor modifications [118].  
 
4.1.1 Excision and Cannulation of the Heart 
The mouse was anesthetized with the isoflurane. The anesthetized mouse was injected 
intraperitoneally with 0.5 ml heparin (100 IU/ml in phosphate buffered saline (PBS)). After 
few minutes, the chest was wiped with 70% ethanol and opened with small scissors. Forceps 
were used to peel the rib cage to expose the heart. The heart was lifted gently with forceps, 
the pulmonary vessels were identified, and the aorta was cut between the carotid arteries. The 
excised heart was placed immediately in a 60 mm dish containing 10 ml of perfusion buffer. 
Extraneous tissue was removed, and the heart was transferred to a new 60 mm dish with 
perfusion buffer. The heart was cannulated using fine-tip forceps to slide the aorta onto the 
cannula under magnification so that the cannula was above the aortic valve. The aorta was 
tied to the cannula with 6/0 silk thread and perfusion was started immediately. Total time to 
cannulate the heart was less than one minute. 
 
4.1.2 Perfusion and Enzymatic Digestion of the Heart 
After cannulation, the heart was perfused with perfusion buffer for 4 minutes at a flow rate of 
4 ml/min to flash blood and extracelluar calcium from the vasculature (Removal of calcium 
to stop contraction). After 4 minutes, perfusion buffer was replaced with myocyte digestion 
buffer and the heart was perfused for 3 minutes at a flow rate of 4 ml/min. Myocyte digestion 
buffer was collected and discarded. 15 µl of 100 mM CaCl2 was added to the myocyte 
digestion buffer in the reservoir and continued to perfuse the heart for 8 minutes at a flow rate 
of 4 ml/min. The total digestion time was about 11 minutes. After enzymatic digestion, the 
heart became swollen and slightly pale. 
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4.1.3 Myocyte Dissociation 
Once enzymatic digestion of the heart was completed, it was cut from the cannula just below 
the atria using sterile fine scissors. The ventricles were placed in sterile 60-mm Valmark dish 
containing 2.5 ml of myocyte digestion buffer. From this point forward all the steps were 
performed under a laminar flow culture hood using sterile technique. The ventricles were 
teased into 10 to 12 pieces with fine tip forceps, and 5 ml of myocyte stopping buffer was 
added to the dish. The digested tissue was gently pipetted up and down several times through 
a sterile plastic transfer pipette. The cell suspension was transferred to a 15-ml polypropylene 
conical tube. The plate was rinsed with 2.5 ml of myocyte stopping buffer and combined with 
the cell suspension to a final volume of 10 ml. The digested heart tissue was further 
dissociated, using sterile plastic transfer pipettes until all the large pieces of the heart tissue 
were dispersed in the cell suspension. The myocytes were allowed to sediment by gravity for 
a few minutes in 15-ml tube. The tube was centrifuged for 3 minutes at 300 rpm. The pellet 
was resuspended gently in 10 ml myocyte stopping buffer, and the supernatant containing 
non-myocytes was transferred to a 50 ml tube for cardiac fibroblasts preparation. 
 
4.1.4 Calcium Re-introduction   
Three 15 ml tubes containing 10 ml myocyte stopping buffer with following calcium 
concentration were prepared. 
     1) 100 µM calcium (10 µl of 100 mM CaCl2 in 10 ml Myocyte Stopping Buffer) 
     2) 400 µM calcium (40 µl of 100 mM CaCl2 in 10 ml Myocyte Stopping Buffer)  
                 3) 900 µM calcium (90 µl of 100 mM CaCl2 in 10 ml Myocyte Stopping Buffer) 
A three-step calcium reintroduction to myocytes was performed as follows. The myocytes 
were centrifuged for 3 min at 300 rpm. The supernatant was removed, and the pellet was 
resuspended with 10 ml of myocytes stopping buffer from tube 1. The above steps were 
repeated with myocyte stopping buffer from tube 2 and 3 containing 400 µM and 900 µM 
calcium respectively. Finally, the pellet was resuspended with myocyte plating medium and 
cells were incubated at 37°C containing 1.2 mM of calcium.   
 
4.1.5 Culture of Cardiac Myocytes 
The myocytes were platted on the laminin coated 6 well dishes. The plates were incubated in 
a 2.5% CO2   at 37°C and cells were allowed to attach. After two hours the medium was 
aspirated and cell debris was removed by washing with 2 ml of myocyte plating medium. 2 
ml of myocyte plating medium was added to each well and plates were transferred to the 
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incubator. Approximately 80% cells were found to be rod shaped. The cells were retained in 
myocyte plating medium over night and were treated with LPS or were used for cell viability 
assay. Fig 4.1 shows a photomicrograph of adult mouse cardiac myocytes plated on laminin 
coated plate.  
 
Figure 4.1 Adult mouse primary cardiac myocytes after plating on laminin coated dishes 
containing myocyte plating medium. 
 
4.1.6 Preparation of Cardiac Fibroblast 
Mouse cardiac fibroblasts were obtained from the hearts by differential centrifugation of 
cardiac cells released after enzymatic digestion of the hearts as mentioned in section 3.1.3. 
Supernatants containing non-myocytes from 2-3 hearts were pooled and centrifuged at 1800 g 
for 5 minutes.  
The supernatant was discarded, and the pellet was mixed in 10 ml of growth medium 
(DMEM) containing 10% Fetal Calf Serum and Gentamicin (28 µg). The cell suspension was 
transferred to a 100 mm non-coated cell culture dish, and the cell culture dish was transferred 
to humidified incubator with 5% CO2 at 37°C. After 2 hours the medium was aspirated, and 
the cell culture dish was washed with fresh growth medium (DMEM) to remove the 
unattached cells. The attached cells (cardiac fibroblast) were maintained and propagated in 
growth medium (DMEM) (Fig. 4.2). Cells were split at 100% confluency and plated into 6 
well plates for further experiment. 
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Figure 4.2 Mouse primary cardiac fibroblasts after 100% confluency 
 
4.2 Assay of mRNA Expression Levels 
General reference: www.appliedbiosystems.com  
Real-time quantitative PCR (qPCR) was used to investigate the mRNA expression levels of 
five target genes in LPS treated mouse cardiac fibroblasts and cardiac myocytes. Real-Time 
qPCR is an advanced PCR technique that can amplify and simultaneously quantify a targeted 
DNA molecule. In real-time PCR, DNA amplification is detected in “real- time” during early 
phases of PCR when the PCR product increases exponentially (Fig. 4.3).  
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Figure 4.3 In Real-Time PCR, the exponential phase gives off the most precise and accurate 
data for quantification (Fig A). The PCR cycle at which the sample reaches a fluorescent 
intensity above background is called the Cycle Threshold (Ct) (Fig B). The Ct value is used 
to quantify the expression levels of the target gene. By comparing the Ct values of samples of 
unknown concentration with a series of standards, the amount of template DNA in an 
unknown reaction can be accurately determined (www.appliedbiosystems.com). 
 
To assess mRNA expression levels of five target genes in LPS treated cardiac cells by real 
time qPCR, total RNA was extracted from the treated and non-treated cells. The mRNA was 
reverse- transcribed using the TaqMan Reverse Transcription Reagent Kit and subsequently 
real-time qPCR of each sample was run in triplicates using TaqMan Pre-developed Assay 
Reagents (TaqMan PDARs) and ABI Prism 7900 Sequence Detection System and Software 
(Applied Biosystems). TaqMan PDARs consists of a forward primer, a reverse primer and an 
oligonucleotide probe designed to amplify specific target sequences in cDNA samples using 
the 5´ nuclease activity. The oligonucleotide (Taqman probe) probe is dual labeled and 
comprises a reporter dye for example, 6-carboxy fluorescin (FAM) dye linked to the 5´ end of 
the probe, a nonfluorescent quencher (NFQ) at the 3´ end of the probe. 
 
For quantitation of gene expression in real-time PCR, relative standard curve method 
(relative quatitation) was applied. Relative standard curve method quantifies differences in 
the expression levels of target gens between treated and non-treated samples. The data output 
is expressed as a fold-change or a fold-difference of expression levels. A relative standard 
curve method is used to quantify expression of both target gene and housekeeping gene. To 
generate a standard curve a dilution series of RT-reaction is made and run for both the target 
and the endogenous control gene. However, to assay mRNA expression levels of the genes by 
real time qPCR, the entire procedure is described as follows. 
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4.2.1 RNA Isolation 
General reference: www.qiagen.com & www.invitrogen.com 
Total RNA was extracted from cardiac fibroblasts by using Qiagen RNeasy Mini Kit, 
whereas RNA from cardiac myocytes was isolated by using both Qiagen RNeasy Mini Kit 
and TRIzol
® 
reagent. The TRIzol
® 
reagent, a mono-phasic solution of phenol and guanidine 
isothiocyanate is known to maintain the integrity of RNA based on the principle of phase 
separation. TRIzol
® 
reagent method involves sample homogenization with TRIzol
® 
reagent, 
phase separation and precipitation of RNA. The eluted RNA from Qiagen spin column and 
RNA obtained from TRIzol
® 
reagent method were stored at -80°C until further use. 
 
4.2.1.1 RNA Isolation from Cardiac Fibroblasts 
Cardiac fibroblasts were seeded at a density of 3x105 cells/well using 6 well plates. Next day, the 
cells were incubated with and without LPS in a humidified chamber at 37°C for 3 hours. After 
stimulation with LPS, the medium was aspirated and cells were washed with (2 ml/well) saline 
water and were immediately lysed by adding 350 µl of lysis buffer. The cell lysates were 
transferred to eppendorf tube and were further homogenized using 25G needle. 70% ethanol (350 
µl) was added to cell lysates. Cell lysates were transferred to RNA spin column. RNA was eluted 
with elution buffer. RNA concentration was measured using Nano-Drop spectrophotometer and 
then RNA was stored at -80°C until further use.  
 
4.2.1.2 RNA Isolation from Cardiac Myocytes 
For cardiac myocytes Qiagen RNA spin column method was not able to produce desirable 
concentration of RNA. Therefore, TRIzol
®  
reagent method was used to get required amount 
of RNA. After washing, 1ml of TRIzol
®  
reagent was immediately added to each well. The 
cells were lysed by pipetting up and down several times and were proceeded to phase 
separation. The homogenized samples were incubated for 5 minutes at room temperature to 
permit complete dissociation of the nucleoprotein complex and 0.2 mL of chloroform was 
added. The tubes were shaken vigorously and were incubated for 2–3 minutes at room 
temperature. The samples were centrifuged at 12,000 × g for 15 minutes at 4°C and the 
aqueous phase of the samples was transferred into a new tube and proceeded to the RNA 
isolation procedure. Then, as a carrier, RNase-free glycogen (7 μg) was added to the aqueous 
RNA solution. To precipitate RNA, 100% isopropanol (0.5 ml) was added and tubes were 
incubated at room temperature for 10 minutes. To pellet the precipitated RNA, the tubes were 
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centrifuged at 12,000 × g for 10 minutes at 4°C and the pellet was washed with 1 ml of 75% 
ethanol. The tubes were vortexed briefly and centrifuged at 7500 × g for 5 minutes at 4°C. 
Supernatant was discarded and RNA pellet was air dried for 5–10 minutes at room 
temperature. The RNA pellet was resuspended in RNase-free water and incubated in a 
heating block at 55°C for 10–15 minutes. The RNA concentration was determined using 
Nano-Drop spectrophotometer and RNA was stored at -80°C until further use.  
 
4.2.2 Reverse Transcription 
Reverse transcription (RT) is a process in which single stranded RNA is transcribed into 
complementary DNA (cDNA) by Reverse Transcriptase Enzyme (RNA-dependent DNA 
polymerase). The extremely unstable nature of RNA has made the cDNA popular for a wide 
variety of experimental purposes; from determining the level of gene expression for a few 
genes to large-scale screening among different biological systems. In 1970s Howard Temin 
and David Baltimore discovered Reverse Transcriptase enzyme independently [119]. 
 
A RT-reaction requires RNA, a primer and reverse transcriptase.  In this reaction, three types 
of primers can be used; oligo (dT) primers, random (hexamer) primers or gene specific 
primers depending upon subsequent analysis. In this study, RT-reactions were carried out by 
using random (hexamer) primers supplied in TaqMan Reverse Transcription Reagents Kit 
(Applied Biosystems). After quantification, the concentration of RNA was adjusted to 50 
ng/µl in all the samples. Each RT-reaction was carried out in a total volume of 50 l. For 
cardiac fibroblasts, 100 ng of total RNA was used in an RT reaction (50µl), whereas for 
cardiac myocytes 500 ng of total RNA was reversed transcribed. A basic RT-reaction 
includes following. 
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Reagents Volume ( l) 
10x RT-buffer 5 
 MgCl2 (25 mM) 11 
dNTP (10 mM) 10 
Hexamers (50 mM) 2,5 
Rnasin (20 U/µl) 1 
MultiScribe RT (50 U/µl) 1,25 
H2O 17,25 
RNA (100 ng) 2 
Total 50 
 
The RT reaction mixtures were incubated in thermal cycler 2720 (Applied Biosystems). The 
thermal cycler 2720 was programmed as follows.  
 
Table Conditions for RT reaction 
 Step 1  Step 2  Step 3  Step 4  
Temperature(
◦
C)  25  48  95  4  
Time  10 min  30 min  5 sec  ∞  
 
The cDNA samples were stored at -20°C until further use. 
 
4.2.3 TaqMan
® 
Real-Time PCR amplification  
Real-time quantitative PCR (qPCR) of each sample was run in triplicates in 96 wells plates 
using TaqMan Pre-Developed Assay Reagents, the ABI Prism 7900 Sequence Detection 
System and software (Applied Biosystems, Foster City, CA, USA) according to the 
manufacturer’s instructions. A standard curve was obtained from 2-fold serial dilutions of 
cDNA, obtained from reverse transcription of total RNA either from cardiac fibroblasts or 
cardiac myocytes. For all specific mRNA amplified, linear inverse correlations were 
observed between the amount of mRNA and CT value (number of cycles at threshold lines). 
Gene expression was presented relative to the levels of 18S rRNA or Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) as the housekeeping genes. A basic TaqMan
 
Real-Time 
PCR reaction includes the following 
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Reagents   Volume ( l) 
Tagman Master Mix (2x) 40 
Taqman gene expression assay (20x) 4 
H2O 31 
cDNA from RT-reaction 5 
TOTAL 80 
 
After adding 5 µl of cDNA, the tubes were vortexed and 25 l of PCR mix per well was 
added to 96 wells plate (Applied Biosystems). MicroAmp™ Clear Adhesive Film was used 
to seal the plates before placing in 7900HT Real-Time PCR System. 7900HT Real-Time PCR 
System uses standard conditions for PCR amplification reaction. The Conditions for PCR 
amplification reactions in a 7900HT Real-Time PCR System are listed in the following table. 
 
4.2.4 Data Analysis 
Results from the 7900HT Real-Time PCR System were obtained as Sequence Detection 
Sytem (SDS) 7900HT documents, which were imported to Microsoft Excel, (Microsoft 
Corporation, USA, version 2007). Quantification of the expression levels of genes in LPS 
stimulated and control mouse cardiac fibroblasts and cardiac myocytes samples was 
performed by a standard curve method.  Gene expression was presented relative to the levels 
of 18S rRNA or GAPDH as follows.  
                                                Expression of gene A   
Normalization of gene A =   
                                        Expression of Human 18S rRNA or Mouse GAPDH                                                                                              
 
Normalization and other statistical analysis of data were performed by using Microsoft Excel 
2007 and GraphPad Prism version 4. 
 
  
 Hold  Hold  Cycles(40 cycles)  
Temperature   50
◦
C  95
◦
C   95
◦
C  60
◦
C  
Time  2 min  10 min  15 sec  1 min  
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4.3 Western Blot Analysis 
Western blotting is a powerful and well-known tool to detect and quantify a protein of 
interest in a complex mixture [120]. The technique detects protein samples immobilized on a 
nitrocellulose or polyvinylidene fluoride (PVDF) membrane. There are two types of Western 
blotting techniques i.e. direct and indirect Western blotting. The direct Western blotting 
involves a reporter-labeled primary antibody that directly binds to the target protein, whereas 
the indirect detection involves a labeled secondary antibody [121] that binds to a non-labeled 
primary antibody (Fig. 4.4). Direct Western blot analysis takes less time than the indirect 
since further incubation with a secondary antibody is not necessary in direct Western blotting. 
In addition, background signal due to cross-reactivity of secondary antibody can  also be 
avoided  in direct technique [122]. 
 
 
 
 
 
 
 
 
 
Figure 4.4 Direct (A) and indirect (B) western blotting methods. In panel A, labeled primary 
antibody creates a detectable signal by binding to antigen on the membrane and reacting with 
the substrate. In panel B, unlabeled primary antibody binds to the antigen and a labeled 
secondary antibody binds to that primary antibody to react with the substrate [123]. 
 
The direct method generally shows less sensitivity than indirect detection method and is 
preferably used only when the target is relatively abundant. A conventional indirect Western 
blot that was used in the experiment begins with resolving of protein samples by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) and then electrophoretically 
transferring to the membrane. After blocking, the membrane is incubated with a primary 
antibody (poly- or monoclonal). The membrane is then washed and incubated with an 
enzyme-conjugated secondary antibody that has specific affinity for primary antibody. After 
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washing again, the membrane is incubated with an appropriate enzyme substrate. The signal 
is either visually detected, if a colorimetric substrate was used, or is detected with X-ray film 
or chemiluminescence/fluorescence signals which are recorded by using digital imaging 
system. The remarkable advances in Western blotting have been made and now, highly 
sensitive-enhanced chemiluminescent substrates, imaging systems and, a wide variety of 
photostable fluorophores are commercially available. The widespread use of extremely 
sensitive chemiluminescent substrates [124, 125] has resulted in nearly avoiding the use of 
radioisotope-labeled probes. Protein A or G labeled with 
125
I was once commonly used as a 
secondary detection reagent; however, the enhanced chemiluminescent substrates can detect 
proteins down to the low-femtogram level with high signal-to-noise ratios [123]. In this 
study, Western blot analyses of target proteins were performed as follows.  
 
4.3.1 Cell preparation  
Protein lysates were prepared from LPS stimulated and control mouse cardiac fibroblasts and 
cardiac myocytes. After stimulation with LPS (1 µg/ml) for 3 , 6 and 24 hours at 37°C the 
cells were washed with saline water and were lysed with protein lysis buffer containing 10% 
SDS and 10 mM Tris-HCl (pH 7.4). The samples were homogenized by sonication and then 
assayed for protein concentration. Samples were denatured by heating at 100°C in Laemmli's 
buffer. Heating denatures the proteins, unfolding them completely. The SDS surrounds the 
protein with a negative charge and the β-mercaptoethanol inhibits the reformation of disulfide 
bonds.  
 
4.3.2 Gel electrophoresis and electroblotting 
In gel electrophoresis, the proteins are separated based on their molecular weight. The 
polyacrylamide gel which was used in this study consists of 12% separating gel and 5% 
stacking gel. Samples (20 g) were loaded in each lane of the gel and protein samples were 
run at 25 mA through the stacking gel and thereafter at 50 mA through the separating gel. 
Proteins were separated based on their molecular weight into bands within each lane under 
the wells. One lane was loaded with molecular weight standards, a commercially available 
mixture of proteins with known molecular weights (Bio-Rad). After electrophoresis, the 
separated proteins were electro-transferred from gel to PVDF membrane according to 
manufacturer’s instructions. Briefly, the methanol activated membrane was placed face-to-
face with the gel in a sandwich and the sandwich was placed in blotting buffer. Then current 
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was applied to initiate the transfer. The charged proteins moved from the gel onto the PVDF 
membrane. 
 
4.3.4 Membrane blocking and antibody incubation 
Blocking of membrane with blocking buffer prevents the non-specific interactions between 
membrane and antibodies being used for detection of the target proteins.  After electro-
blotting, the membrane was briefly washed with PBS or TBS. For blocking, the membrane 
was incubated in blocking buffer (5% non-fat dry milk or 5% casein in TBST or PBST, 
respectively) for one hour at room temperature. After washing three times for 5 minutes each 
with appropriate washing buffer, the membranes were incubated with primary antibody in 
primary antibody dilution buffer with gentle agitation overnight at 4°C. The membrane was 
washed three times for 5 minutes each and incubated with horseradish peroxidase (HRP) 
conjugated species appropriate secondary antibody for one hour at room temperature. The 
unbound secondary antibody was washed and preceded to detection step. For detection of the 
target proteins, the membranes were incubated with 6 ml LumiGLO with gentle agitation for 
1 minute at room temperature. The signals were recorded by using KODAK Image Station 
4000R Digital Imaging System and KODAK Molecular Imaging Software.  Finally, 
expression levels of target proteins were determined by densitometric analysis using KODAK 
Molecular Imaging Software. 
 
4.4 Cell Viability 
The trypan blue exclusion assay is performed to determine the number of viable cells in a 
given cell culture. The test is based on the principle that live cells exclude trypan blue, 
whereas dead cells stain with trypan blue. To perform the test, cell suspension is simply 
mixed with dye and is visually examined to determine whether cells take up or exclude the 
dye.  
 
In this study, trypan blue exclusion assay was performed to evaluate the cell viability of LPS 
stimulated and control primary mouse cardiac myocytes. After isolation, the cardiac 
myocytes were plated in 6 wells plates and kept in a humidified chamber overnight at 37 C. 
Before treatment with LPS, the dead cells were removed and the fresh culture medium was 
added to each well. For viability test, the cells were incubated in the absence and presence of 
LPS (0.1 g/ml and 10 g/ml) and cell viability was determined at four different time points 
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after stimulation. To count the number of dead cells, 50 µl of filtered trypan blue was added 
to each well, waited for two minutes to stain the dead cells. Total cells including dead and 
viable cells were counted and percentage of viable cells was determined. Statistical analyses 
were performed by using Graph Pad Software (Graph Pad Prism 4.0).  
 
4.5 Statistical Analysis 
All the data were given as means ±SE. Two tailed Student’s t-test was applied for statistical 
comparisons of two groups, whereas one-way ANOVA and two-way ANOVA with 
Bonferroni’s test were performed for the comparison of multiple groups. P values <0.05 were 
considered to be statistically significant. 
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5. RESULT 
5.1. Expression of TNF-α and IL-1β mRNA in LPS Stimulated 
Cardiac Fibroblasts and Cardiac Myocytes 
To investigate the effects of LPS on mRNA expressions of TNF-α and IL-1β, adult mouse 
cardiac fibroblasts and cardiac myocytes were stimulated for 3 hours with increasing 
concentrations of LPS as indicated in Fig. 5.1 and 5.2. As shown in Fig. 5.1, real-time 
quantitative PCR (qPCR) analysis revealed robust induction of TNF-α and IL-1β mRNA 
expressions in LPS (1µg/ml) stimulated cardiac fibroblasts and cardiac myocytes. The 
mRNA expression levels of TNF-α and IL-1β in cardiac fibroblasts were up-regulated 20 fold 
(P<0.05; Fig. 5.1A) and 23 fold (P<0.05; Fig. 5.1B) respectively, whereas in cardiac 
myocytes TNF-α mRNA expression levels were elevated 10 fold (P<0.0001; Fig. 5.1C) and 
that of IL-1β were increased 5 fold (P<0.0001; Fig. 5.1D) above the control levels (non-
stimulated). In addition, we investigated the concentration dependent effects of LPS on the 
mRNA levels of the two cytokines in primary cardiac cells.  
 
Figure 5.1 Real-time qPCR analysis demonstrating mRNA levels of TNF-α and IL-1β in 
adult mouse cardiac fibroblasts (A and B) and myocytes (C and D) incubated in the absence 
or presence of LPS (1 µg/ml ; 3 hours). Data are presented as ratios of  TNF-α  or IL-1β mRNA 
levels relative to levels of 18S rRNA. Mean ± SEM, *P<0.05 vs. control group.  
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Cardiac fibroblasts and cardiac myocytes were stimulated with 0.001 µg/ml, 0.01µg/ml and 
0.1 µg/ml of LPS for 3 hours, and the mRNA levels were investigated using real-time qPCR 
(Fig. 5.2). GAPDH mRNA levels were used as the housekeeping gene.  
 
 
Figure 5.2 Real-time qPCR analysis demonstrating dose-dependent effects of LPS (0.001 
µg/ml, 0.01 µg/ml and 0.1 µg/ml; 3hours) on mRNA levels of TNF-α and IL-1β in adult 
mouse cardiac fibroblasts (A and B) and myocytes (C and D), respectively.  Data are 
presented as ratios of TNF-α or IL-1β mRNA levels relative to levels of GAPDH mRNA. Mean 
± SEM, *P<0.05 vs. control group.  
 
Both cardiac fibroblasts and cardiac myocytes consistently responded to increasing 
concentrations of LPS.  In cardiac fibroblasts, dramatic concentration dependent increases of 
TNF-α and IL-1β mRNA levels were observed in response to LPS. As shown in Fig. 5.2A, 48 
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fold, 64 fold and 74 fold elevations of TNF-α mRNA levels were seen in response to 0.001 
µg/ml, 0.01 µg/ml and 0.1 µg/ml of LPS, respectively (P<0.001). The induction of IL-1β 
mRNA levels in cardiac fibroblasts in response to LPS was even more dramatic ranging from 
742 fold to 1253 fold elevation of IL-1β mRNA levels in response to the lowest and highest 
concentrations of LPS, respectively (P<0.001), compared to non-stimulated cells (Fig. 5.2B). 
Adult cardiac myocytes also responded with increasing levels of TNF-α and IL-1β mRNA 
levels in the presence of increasing concentrations of LPS. However, fold induction of TNF-α 
and IL-1β in response to LPS was modest compared with that in cardiac fibroblasts. In 
cardiac myocytes, only 0.1 μg/ml of LPS resulted in statistically significant elevation of 
TNF-α mRNA levels, whereas both 0.01 μg/ml and 0.1 μg/ml of LPS resulted in statistically 
significant elevation of IL-1β mRNA levels. For example, stimulation of cardiac myocytes 
for 3 hours with 0.1 μg/ml LPS increased 3.6 fold and 4.3 fold elevations of TNF-α and IL-1β 
mRNA levels, respectively (P<0.05) (Fig. 5.2C and 5.2D) 
 
Figure 5.3 Real-time qPCR analysis depicting mRNA levels of CCN2 and CCN5 in adult 
mouse cardiac fibroblasts (A and B) and cardiac myocytes (C and D) stimulated  with LPS 
(1 µg/ml: 3hours). Data are presented as ratios of CCN2 or CCN5 mRNA levels relative to 
levels of 18S rRNA. Mean ± SEM, *P<0.05 vs. control group. 
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5.2 Expression of CCN2, CCN5 and GDF15 mRNA in LPS 
Stimulated Cardiac Fibroblasts and Cardiac Myocytes 
Recent studies have demonstrated that the matri-cellular proteins CCN2 and CCN5 and the 
secreted macrophage inhibitory cytokine GDF15 play cardioprotective roles under ischemia 
and reperfusion or chronic pressure over load induced heart failure. To investigate how the 
mRNA levels of CCN2, CCN5 and GDF15 in cardiac fibroblasts and cardiac myocytes 
respond to increasing concentrations of LPS, the mRNA levels were assayed by real-time 
qPCR. First, cardiac fibroblasts and cardiac myocytes were stimulated with a single 
concentration of LPS (1 µg/ml) and the mRNA levels of CCN2 and CCN5 were assessed by 
real-time qPCR. As shown in Fig. 5.3A, the mRNA levels of CCN2 were significantly down-
regulated (3.5 fold; P<0.05) in response to LPS (1 µg/ml) in cardiac fibroblasts compared to 
control cells. In cardiac myocytes, no significant regulation of CCN2 mRNA expression was 
observed in LPS treated cells (Fig 5.3C). Similarly, the mRNA levels of CCN5 were found to 
be significantly down-regulated (2.2 fold; P<0.05) in LPS stimulated cardiac fibroblasts (Fig 
5.3C) whereas in cardiac myocytes the down-regulation of CCN5 mRNA expression did not 
reach to the significant level in LPS treated cells compared to non-treated cells (Fig. 5.3D).   
 
To investigate the concentration dependent effects of LPS on gene expression of these three 
target proteins, the primary cardiac cells were treated with three different concentrations of 
LPS (0.001 µg/ml, 0.01 µg/ml and 0.1 µg/ml). In cardiac fibroblasts, the mRNA levels of 
CCN2 were down-regulated in response to all three concentrations of LPS though statistically 
significant down-regulation was found only in the cells with the lowest dose of LPS 
stimulation (1.4 fold P<0.05) (Fig. 5.4A). In cardiac myocytes, the mRNA levels of CCN2 
were induced in response to all three increasing concentrations of LPS though no significant 
induction was seen in the stimulated cells compared to the control cells (Fig. 5.4D). The 
mRNA levels of CCN5 were although not robustly but significantly and consistently down-
regulated in cardiac fibroblasts in response to all three increasing concentrations of LPS (Fig. 
5.4B). Exposure of LPS (0.001 µg/ml, 0.01 µg/ml and 0.1 µg/ml) resulted in 1.3 fold 
(P<0.05), 1.4 fold (P<0.05) and 1.4 fold (P<0.001) decreases of CCN5 mRNA levels 
respectively compared to the control cells. On the contrary, the mRNA levels of CCN5 tend 
to increase in LPS stimulated cardiac myocytes compared to control cells though the 
inductions were not statistically significant (Fig. 5.4E). In addition, we also investigated 
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GDF15 mRNA expression in response to three increasing concentrations of LPS both in 
cardiac fibroblasts and cardiac myocytes. The mRNA levels of GDF15 were down-regulated 
1.7 fold (P<0.05) in cardiac fibroblasts treated cells with the lowest concentration of LPS 
(0.001 µg/ml), whereas down-regulation of GDF15 mRNA expressions did not reach to the 
significant level in cells stimulated with 0.01 µg/ml and 0.1 µg/ml of LPS compared to 
control cells (Fig. 5.4C). However, in cardiac myocytes, GDF15 mRNA levels were elevated 
in cell cultures exposed to 0.01 μg/ml (4.1 fold; p<0.05) and 0.1 μg/ml (6 fold; P<0.05) of 
LPS compared to control cells (Fig. 5.4F).  
 
Figure 5.4 Real-time qPCR analysis depicting mRNA levels of CCN2, CCN5 and GDF15 in 
adult mouse cardiac fibroblasts (A, B and C) and cardiac myocytes (D, E and F) treated with 
increasing concentrations of LPS (0.001 µg/ml, 0.01 µg/ml and 0.1 µg/ml) for 3 hours. Data 
are presented as ratios of CCN2, CCN5 or GDF15 mRNA levels relative to levels of GAPDH 
mRNA. Mean ± SEM, *P<0.05 vs. control group.  
 
5.3 Protein Expression of TNF-α and IL-1β 
To assess the protein contents of the two pro-inflammatory cytokines TNF-α and IL-1β in 
adult cardiac fibroblasts and cardiac myocytes exposed to LPS, the cells were treated in the 
absence or presence of LPS (1 µg/ml) for 3 hours. Western blot analysis of extracts of cardiac 
fibroblasts revealed that the protein levels of TNF-α (Fig 4.5A) and IL-1β (4.5B) were 
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induced 2.9 fold (P<0.01) and 3.78 fold (P<0.005) respectively in LPS stimulated cells 
compared to control cells.  On the contrary, in cardiac myocytes TNF-α and IL-1β contents 
remained unchanged in LPS-treated cells compared to control cells (Fig. 5.5).  
 
Figure 5.5 Western Blot analysis of TNF-α and IL-1β levels in adult mouse cardiac 
fibroblasts (A and B) and cardiac myocytes (C and D) incubated in the absence or presence 
of  LPS (1 µg/ml) for 3 hours. Histograms demonstrate densitometric analysis of the 
corresponding immunoreactive bands (precursor TNF-α; 25 KD and precursor IL-1β; 31 
KD). Mean ± SEM, *P<0.05 vs. control group. 
 
 
5.4 Protein Expression of CCN2, CCN5 and GDF15 
In order to assess CCN2, CCN5 and GDF15 contents in cardiac fibroblasts exposed to LPS, 
cardiac fibroblasts were stimulated with LPS (1 µg/ml) for 3 hours, 6 hours and 24 hours. 
Western Blot analysis of protein lysates of cardiac fibroblasts demonstrated that the CCN2 
protein contents were down-regulated in LPS-treated cells compared to control cells in a 
time-dependent manner (3 hours, 82% of control cells, P<0.05; 6 hours, 90% of control cells, 
P>0.05; 24 hours, 52% of control cells, P<0.05). However, no significant regulation of CCN2 
protein expression was seen in stimulated cardiac myocytes compared to control cells after 6 
hour LPS stimulation (P>0.05; Fig. 5.6D). Assessment of protein contents of CCN5 and 
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GDF15 was also attempted, but Western blot analysis of extracts from control and LPS 
stimulated cardiac myocytes did not distinct immunoreactive bands. 
 
Figure 5.6 Western Blot analysis of CCN2 levels in adult mouse cardiac fibroblasts (A-C) 
and cardiac myocytes (D) incubated  in the absence or presence of LPS (1 µg/ml). Cardiac 
fibroblasts were stimulated for 3(A) hours, 6(B) hours and 24(C) hours, whereas cardiac 
myocytes were stimulated for 6(D) hours. Histograms depict densitometric analysis of the 
corresponding (38 KD) immunoreactive bands. Mean ± SEM, *P<0.05 vs. control group. 
 
 
5.5 Cell Viability 
Assessment of LPS-induced cell death of adult cardiac myocytes was investigated by trypan 
blue exclusion assay. First, a time dependent experimental setup with two different 
concentrations of LPS (0.1 µg/ml and 10 µg/ml) was designed for the assessment of trypan 
blue staining of dead cardiac myocytes. Cell viability was decreased significantly and 
consistently after LPS treatment (Fig. 5.7A). Indeed, exposure to 0.1 µg/ml and 10 µg/ml of 
LPS appeared to induce similar extents of cell death (Fig. 5.7A). After 6 hours, 12 hours and 
24 hours viability of cardiac myocytes exposed to 0.1 µg/ml LPS was 60.5%(P<0.05; Control 
cell viability 71.5%), 42% (P<0.001; Control cell viability 68.5%) and 43.5% (P<0.001); 
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Control cell viability 61%) respectively, whereas viability of cardiac myocytes exposed to 10 
µg/ml LPS was 61.5% (P<0.05; Control cell viability 71.5%), 46% (P<0.001; Control cell 
viability 68.5%) and 34.5% (P<0.001; Control cell viability 61%) at 6 hours, 12 hours and 24 
hours, respectively. In the second experiment, the old myocyte plating medium was replaced 
with fresh myocyte plating medium prior to start the experiment. Cell viability was assessed 
at 0 hours, 12 hours and 24 hours after LPS treatment (0.1 µg/ml). As shown in Fig. 5.7B cell 
viability was decreased in the LPS treated cells both at 12 hours (56% treated cell viability vs 
78.96% control cell viability; P<0.01) and 24 hours (65.67% treated cell viability vs 79.67% 
control cell viability; P>0.05) though the decrease of cell viability after 24 hour LPS 
treatment cells did not reach to the significant level compared to control cells. 
 
Figure 5.7 Trypan blue exclusion assay of cell viability in adult mouse cardiac myocytes 
after LPS stimulation. Figure A and B represent the percentage of cell survival in LPS treated 
cell cultures and their corresponding control cell cultures at the indicated time points. Data 
are presented as a percentage of living cells. P<0.05 vs. control group (Mean ± SEM) denotes 
statistically significant variation. 
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6. DISCUSSION 
Mammals including humans inevitably come into contact with gram-negative bacteria and 
bacterial wall-associated LPS. Low-dose LPS is thought to play a positive role for the host by 
sensitizing the immune response and eventually enhancing resistance to infections and 
malignancies. However, the presence of a large amount of LPS exerts deleterious effects i.e., 
dramatic pathophysiological reactions e.g., fever, leukopenia, tachycardia, hypotension and 
multi-organ failure etc. [126]. Humans show an exquisite sensitivity to LPS with lethal range 
as low as 1 µg to 2 µg [127]. Lang and his colleagues injected rats with doses of endotoxin 
ranging from 0.01 µg/100 g body weight to 1000 µg/100 g body weight and reported that 
doses of 10 µg/100 g body weight or fewer were consistently nonlethal over 72 hours [128]. 
They also reported that doses of 100 µg/100 g body weight and 1000 µg/100 g body weight 
resulted in approximately 10% and 50% lethality in rats respectively after 24 hours.  
McDonough  and his colleagues investigated myocardial performance in rodents exposed to 
lethal (1000 μg/100 g body weight and 100 µg/100 g body weight) and nonlethal (10 µg/100 
g body weight and 1 µg/100 g body weight) doses of LPS by examining cardiac function ex-
vivo, as used by Lang et al. [128]. They reported that the administration of endotoxin resulted 
in a loss of myocardial physiological reserve and this loss of myocardial reserve increased 
with increasing doses of endotoxin. Cardiac output was extremely sensitive to the toxic 
effects of endotoxin especially at elevated preload and afterload conditions. Coronary flow 
was decreased and thus coronary vascular resistance was elevated [129]. Shiying Tao and 
Thomas McKenna demonstrated that LPS (0.001-0.1µg/ml for 6 hours incubation) resulted in 
direct negative effects on adult rat cardiac myocyte contractile function i.e., diminished 
contractility by inducing NO synthase activity [130]. Rat hearts perfused with LPS (4 µg/ml) 
for 30 minutes showed depressed function as revealed by decreased left ventricular developed 
pressure and reduced peak rate of contraction and relaxation  [131]. Adult mouse 
cardiomyocyte exposure to LPS (sub-lethal dose, 1 μg /ml for 4 to 6 hours incubation)   leads 
to contractile dysfunction and intracellular Ca
2+ 
mishandling by inducing reactive oxygen 
species (ROS) accumulation, protein damage and apoptosis [132]. However, inflammatory 
responses of adult mouse cardiac fibroblasts and cardiac myocytes to increasing 
concentrations of LPS are yet poorly understood. 
 
According to prevailing studies, LPS upregulates the pro-inflammatory cytokines TNF-α and 
IL-1β via activation of cell signalling cascades leading to the NF-κB pathway activation 
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[133]. TNF-α and IL-1β both depress human myocardial function in a dose-dependent 
fashion [134]. In this present study, we investigated the mRNA expression of TNF-α and IL-
1β in the primary adult mouse cardiac fibroblasts and cardiac myocytes in dose-dependent 
fashion after 3 hour LPS treatment. The finding was consistent with previous studies. LPS 
induced mRNA levels of TNF-α and IL-1β both in cardiac fibroblasts and cardiac myocytes 
in the dose-dependent manner. Both the absolute induction levels of mRNA and the relative 
expression levels normalized to housekeeping gene (18s rRNA or GAPDH mRNA) of these 
two cytokines in LPS treated cardiac fibroblasts were much higher than that in cardiac 
myocytes.  In the normal heart, non-muscle cells comprise two-thirds of the cell population of 
which the majority are cardiac fibroblasts [135]. A growing body of evidence infers that 
cardiac fibroblasts play a pivotal role in inflammation, tissue repair, fibrosis and 
organogenesis by producing growth factors, cytokines, ECM proteins and proteases [136]. 
Protein expression levels of these cytokines were also highly induced in cardiac fibroblasts 
though it was only investigated by treating the cells with single concentration of LPS (1 
µg/ml). Western blot analysis revealed immunoreactive bands of both cytokines 
corresponding to pre-cursor forms (pre-cursor TNF-α 25 KD; pre-cursor IL-1β 31 KD), but 
the bands corresponding to mature forms (mature TNF-α 17KD; mature IL-1β 15 KD) of 
cytokines were not observed.  However, no significant regulation of these two cytokines at 
protein levels was found in cardiac myocytes after LPS treatment. The difference of induction 
levels of mRNA of these two cytokines between cardiac fibroblasts and cardiac myocytes 
might indicate a molecular mechanism of active secretion from cardiac fibroblasts at 
precursor level but not from cardiac myocytes. Yokoyama and his colleagues demonstrated 
that TNF protein synthesis in cardiac fibroblasts was 20 to 40 fold higher than that in cardiac 
myocytes [137]. They also showed that ANG II increased the mRNA expression and the 
production of biologically active TNF much higher in cardiac fibroblasts rather than in 
cardiac myocytes because of higher density of AT1 receptors in cardiac fibroblasts. Michio 
Miyoshi and colleagues demonstrated that ANG II promotes LPS-induced production of pro-
inflammatory cytokines in dehydrated rats [138]. In addition,Yuanyuan Ji and his colleagues 
reported that ANG II contributes to TLR4 activation in vascular smooth muscle cells through 
AT1 receptors and extracellular signal-regulated kinase 1/2 (ERK1/2) [139]. It is tempting to 
speculate that ANG II and AT1 receptors are also involved in induction of TLR4 mRNA 
levels in cardiac fibroblasts since these cells, as opposed to adult cardiac myocytes, express 
abundant AT1 receptors, proposing a mechanism for the robust pro-inflammatory actions of 
LPS in cardiac fibroblasts.  
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The expression of cardioprotective genes (CCN2, CCN5 and GDF15) were also investigated 
at mRNA and protein levels in LPS treated cardiac fibroblasts and cardiac myocytes. We 
found that LPS down-regulated the expression of CCN2 both at mRNA levels and protein 
levels in cardiac fibroblasts. The regulation of CCN expression is complex and cell specific 
in response to inflammation [140]. Several studies reported that TNF-α is involved in the 
regulation of CCN2 expression mechanisms. TNF-α induces CCN2 expression in synovial 
cells, whereas it inhibits CCN2 expression in chondrocytes [141, 142]. David Abraham et al., 
demonstrated that TNF-α inhibits TGF-β induced CCN2 expression in normal cultured 
fibroblasts via cis-elements located between -244 and -166 of the CCN2 promoter [143]. Fun 
Yu et al., also showed that TNF-α inhibits TGF-β induced CCN2 expression in embryonic 
fibroblasts by swapping the binding preference of p300 from Smad4 to p65 [144]. This 
finding infers that p300 physically binds with p65 rather than Smad4 in the presence of both 
TNF-alpha and TGF-beta and eventually results in inhibition of CCN2 expression. We also 
found that the mRNA expression of CCN5 was down-regulated after LPS treatment though 
CCN5 expression at protein level was not detected by Western blot analysis. Either the 
primary antibody used in Western blot analysis does not have the specificity for murine 
endogenous CCN5 protein or the cellular CCN5 protein levels were too low to detect. No 
previous study has demonstrated down-regulation of CCN5 in response to LPS in cardiac 
fibroblasts. To be speculative, it is tempting to deduce that the down regulation of CCN5 by 
LPS is conferred by the same mechanism that has been described for CCN2, since CCN5 
belongs to CCN family of the genes. Laure Rittié and his colleagues demonstrated that both 
CCN2 and CCN5 mRNA expression levels were strongly down-regulated during wound 
healing in response to skin inflammation [145]. The present study revealed that the mRNA 
expression of GDF15 was significantly down-regulated in adult mouse cardiac fibroblasts 
after 0.001 µg/ml of LPS treatment for 3 hours. However, the role of cardiac GDF15 during 
sepsis is not well elucidated by previous studies. It might be anticipated that either LPS or 
cytokines may interfere the transcription level of GDF15 in cardiac fibroblasts to inhibit the 
mRNA expression. Again, we could not detect GDF15 expression at protein levels in cardiac 
fibroblasts. Either the primary antibody used had not cross-reactivity with murine cells or the 
cellular GDF15 protein levels were too low to detect.  
 
On the other hand in cardiac myocytes, CCN2 and CCN5 mRNA levels tended to increase 
after stimulation with increasing concentrations of LPS although not statistically significant. 
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However, no regulation of CCN2 expression was detected at protein levels in LPS treated 
cardiac myocytes, whereas CCN5 protein expression remained undetectable in cardiac 
myocytes. Our data showed significant up-regulation of GDF15 at mRNA expression levels 
in cardiac myocytes after treatment with increasing concentrations of LPS. Previous studies 
reported that  GDF15 expression was rapidly induced by the pro-inflammatory cytokines 
TNF-α and IL-1β which results in  modulation of macrophage activation and inflammation 
[146]. However, it is yet unknown how the inflammatory cytokines induce GDF15 
expression. Although, GDF15 mRNA was significantly upregulated in LPS-treated cardiac 
myocytes, we were not able to detect GDF15 expression at protein levels after LPS treatment. 
 
We investigated cell death by trypan blue exclusion assay in isolated adult mouse cardiac 
myocytes. LPS (0.1 and 10 µg/ml) significantly decreased cell viability in a time dependent 
manner. In our first experiment LPS-treated cells displayed significantly decreased viability 
after 6 hours, 12 hours and 24 hours. The experiment was repeated with minor modification 
by replacing the old myocyte plating medium with fresh myocyte plating medium to avoid 
the background levels of enzymes released before start of the experiment. In the latter 
experiment, LPS significantly decreased cell viability after 12 hours though it showed no 
significant reduction in cell viability after 24 hours. The possible reason for not getting 
significant cell death at the 24 hour time point might be that 24 hours of incubation of cells 
resulted in many dead cells detaching from the surface of the well which might have been 
excluded during counting period and eventually might have given a non-significant reduction. 
Cardiac myocytes have limited ability to regenerate and in heart failure apoptosis results in 
continuous loss of cardiac myocytes  [147]. Several studies reported that LPS induces cardiac 
apoptosis in sepsis [148, 149]. Li et al. reported that a single dose of LPS that results in no 
stress and does not impact on blood pressure is sufficient enough to induce cardiac apoptosis 
via AT1 receptors [150]. Frantz and his colleagues reported that the abundant expression of 
the LPS receptor, TLR4 on cardiomyocytes makes the heart sensitive to LPS [151]. LPS-
induced apoptosis in cardiomyocytes has been shown to be TNF-α dependent via the CD14 
signaling pathway [152]. Sandra demonstrated that TNF-α signaling provokes apoptosis of 
cardiomyocytes through activation of multiple cell death pathways [153]. A putative 
mechanism is that LPS-induced release of TNF-α from cardiac fibroblasts exerts direct 
cytotoxic effects on neighboring cardiac myocytes since release of TNF-α is more robust 
from cardiac fibroblasts than from cardiac myocytes.  
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7. CONCLUSION   
In conclusion, LPS plays a pivotal role in cardiac dysfunction and remodelling by inducing a 
release of inflammatory cytokines in the heart. Our in vitro data demonstrated that LPS 
induces the production of the pro-inflammatory cytokines TNF-α and IL-1β in adult mouse 
cardiac fibroblasts and myocytes suggesting a huge release of TNF-α and IL-1β particularly 
from cardiac fibroblasts. We also reported that LPS downregulates CCN2 and CCN5 
expression in cardiac fibroblasts and induces GDF15 expression in cardiac myocytes. We 
found that LPS decreases cardiac myocyte viability in a time dependent manner. In our future 
studies, we will investigate the cytoprotective effects of recombinant CCN2, CCN5 and 
GDF15 at LPS-induced cell death in cardiac cell cultures. Our group already developed 
transgenic mice with cardiac-restricted over-expression of CCN2. It would also be interesting 
to delineate the effects of LPS in vivo using the CCN2-transgenic mouse model.  
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